| 酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析 |
| 投稿时间：2018-11-25 修订日期：2019-03-05 点此下载全文 |
| 引用本文：林莉莉,张妍,刘志宏,吴珏,宋洪涛.酪酸梭菌肠球菌三联活菌片对晚期非小细胞肺癌患者吉西他滨联合铂类化疗方案影响的回顾性分析[J].药学实践杂志,2019,37(3):268~273 |
| 摘要点击次数: 1504 |
| 全文下载次数: 759 |
|
| 基金项目:福州总医院杰出青年培育项目（2016Q05） |
|
| 中文摘要:目的 通过相关回顾性病例收集研究，探究使用酪酸梭菌肠球菌三联活菌片是否具有提高晚期非小细胞肺癌（NSCLC）患者吉西他滨联合铂类（GP）化疗方案的疗效，减轻化疗带来的毒副作用。方法 调取2014年1月至2018年7月在福州某三甲医院肿瘤科接受GP化疗方案治疗的晚期NSCLC患者的医疗记录，纳入78例患者的相关数据，采用SPSS 25.0软件进行数据统计分析。结果 与对照组相比，使用酪酸梭菌肠球菌三联活菌片对患者的疾病控制率、无进展生存时间的影响具有显著性差异（P值分别为0.048、0.012），对疾病缓解率和不良反应风险的影响均无显著性差异（P>0.05）。结论 在晚期NSCLC患者中，GP化疗方案治疗联合使用酪酸梭菌肠球菌三联活菌片可能提高患者的疗效。 |
| 中文关键词:酪酸梭菌肠球菌三联活菌片 肠道菌群 非小细胞肺癌 吉西他滨 铂类 |
| |
| The effect of clostridium butyricum enterococcus triple viable tablet on GP regimen in advanced NSCLC patients |
|
|
| Abstract:Objective To explore the effect of clostridium butyricum enterococcus triple viable tablet on the efficacy and adverse reactions of gemcitabine plus platinum(GP) regimen for the patients with advanced non-small cell lung cancer(NSCLC).Methods The records of 78 NSCLC patients who treated with GP regimen as first-line palliative chemotherapy were reviewed,and the related data were recorded.Statistical analyses were performed with SPSS 25.0.Results Compared with the control group,the probiotic preparation group showed a significant difference in disease control rate and progression-free survival (P value are 0.048 and 0.012 respectively),while there were no significant differences in objective response rate and the risk of adverse reaction events(P>0.05).Conclusion The clostridium butyricum enterococcus triple viable tablet might improve the efficacy of GP regimen as a first-line palliative chemotherapy for advanced NSCLC patients. |
| keywords:clostridium butyricum enterococcus triple viable tablet gut flora NSCLC gemcitabine platinum |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
